Merck (MRK) Gains from Investment Securities (2009 - 2026)

Merck has disclosed Gains from Investment Securities across 18 years of filings, most recently posting $66.0 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 160.55% year-over-year to $66.0 million; the TTM figure through Mar 2026 stood at $233.0 million (up 5725.0% YoY), while the FY2025 annual figure was $58.0 million, down 54.33% from the prior year.
• Gains from Investment Securities eased to $66.0 million in Q1 2026, from $172.0 million in the prior quarter.
• Over the last five years, Gains from Investment Securities for MRK reached as high as $330.0 million in Q3 2025 and fell as low as -$975.0 million in Q3 2022.
• The 5-year median for Gains from Investment Securities is $14.0 million (2024), against an average of -$59.6 million.
• The widest YoY moves for Gains from Investment Securities: up 243.07% in 2024, down 1265.0% in 2024.
• A 5-year view of Gains from Investment Securities shows it stood at -$132.0 million in 2022, then jumped by 115.91% to $21.0 million in 2023, then jumped by 171.43% to $57.0 million in 2024, then soared by 201.75% to $172.0 million in 2025, then sank by 61.63% to $66.0 million in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered $66.0 million, $172.0 million, and $330.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.